How profitable is Acrivon Therapeutics Inc. (ACRV)?

In FY 2025 (10-K), ACRV converted $235.5M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / ACRV / financials

MAIA (32) TELO (28) TENX (27) SDEV (33) ⌘ Pro Terminal →

Acrivon Therapeutics Inc. (ACRV) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.61 -3.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.60

Acrivon Therapeutics Inc. (ACRV) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $69.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ACRV Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ACRV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Acrivon Therapeutics Inc. (NASDAQ: ACRV) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.61 (-3.01% 1D, market cap $69.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ACRV ranks #691 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ACRV compare to MAIA and TELO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACRV carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MAIA (MAIA Biotechnology Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $67.9M) and TELO (Telomir Pharmaceuticals Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M). Among the 5-stock peer group, ACRV leads on earnings multiple (N/A) while ACRV leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ACRV?

▼

Per ACRV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001781174), Acrivon Therapeutics Inc. generated $235.5M in revenue (-5.7% YoY), -$77.9M in net income, and -$65.3M in free cash flow against $129.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.60 (-0.73%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACRV)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY ACRV SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.75+2.3% Next Q

Q2 (-2Q)

Grade E$1.79-2.8% Next Q

Q3 (-1Q)

Grade E$1.74-7.5% Next Q

Current

Grade E$1.61-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACRV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACRV currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.92) and Max Pain ($1.69) forces dealer call-delta covering toward $3.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACRV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ACRV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ACRV Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $187.9M

FY24

Rev $249.8M

FY25

Rev $235.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$235.5M	52%	-35.7%	-$77.9M	-$65.3M	-45%
FY 2024	$249.8M	52%	-35.7%	-$80.6M	-$68.4M	-45%
FY 2023	$187.9M	52%	-35.7%	-$60.4M	-$42.6M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACRV)

✓Walkthrough of ACRV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ACRV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.60%▲ ASCENDING CHANNEL

2026-11-04O $1.66H $1.66L $1.61C $1.61VOL 228.2K

RES: $2.30SUP: $1.51SMA50: $1.92SMA200: $1.77

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACRV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACRV Butterfly Map → + Track ACRV →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ACRV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACRV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ACRV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACRV)

Health Care Rank #691 of 1015 ⚔️ MAIA vs ACRV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACRV vs. MAIA, TELO, TENX, SDEV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Acrivon Therapeutics Inc. (ACRV) ranks #691 by composite RQD confidence (33/100, grade E) and #697 by equity capitalization ($69.0M). Within this direct 5-issuer industry benchmark cohort, ACRV leads on earnings valuation at N/A trailing P/E, while ACRV leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ACRV currently leads its immediate peer cohort in composite quantitative strength at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ACRV ACTIVE Acrivon Therapeutics Inc.	E	33/100	—	—	-35.0%	-3.01%	$69.0M	Benchmark Subject
MAIA MAIA Biotechnology Inc.	E	32/100	—	—	-35.0%	0.00%	$67.9M	/maia-vs-acrv →
TELO Telomir Pharmaceuticals Inc.	E	28/100	—	—	-35.0%	-2.15%	$67.4M	/telo-vs-acrv →
TENX Tenax Therapeutics Inc.	E	27/100	—	—	-35.0%	+0.56%	$67.4M	/tenx-vs-acrv →
SDEV Stablecoin Development Corporation	E	33/100	—	—	-35.0%	-8.91%	$67.3M	/sdev-vs-acrv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001781174 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Acrivon Therapeutics Inc. (ACRV) reported GAAP revenue of $235.5M (-5.7% vs. FY2024 revenue of $249.8M , and +25.4% cumulative change since FY2023) , GAAP net income of -$77.9M, operating cash flow of -$63.7M, and free cash flow of -$65.3M (+4.5% YoY). On the balance sheet, ACRV closed FY2025 with $129.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$235.5M	-$77.9M	-$63.7M	-$65.3M	$129.7M	—
FY2024 (FY)	2024-12-31	$249.8M	-$80.6M	-$65.7M	-$68.4M	$196.6M	—
FY2023 (FY)	2023-12-31	$187.9M	-$60.4M	-$42.6M	-$42.6M	—	—

3. ACRV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACRV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ACRV compare to MAIA and TELO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ACRV?

Where is ACRV trading relative to its 50-day, 200-day, and 52-week technical levels?

ACRV last traded at $1.61 (-3.01% on volume of 228,226 shares), positioning the stock -16.15% below its 50-day simple moving average ($1.92) and -9.04% below its 200-day simple moving average ($1.77). Across its 52-week range of $1.27 to $3.56, ACRV sits at the 14.8% percentile with a 14-day RSI of 36.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.41 to $1.81).

Direct Sub-Reports: ACRV RQD Cockpit ACRV 12M Forecast ACRV Earnings & Move ACRV Dividends & DRIP ACRV Insiders & 13F ACRV Whale Options ACRV Profit Sankey ACRV News & Why

ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

ACRV — Acrivon Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Acrivon Therapeutics Inc. (ACRV) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.61 (-3.01% 1D, market capitalization $69.0M).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (4/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Acrivon Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. Per the Yahoo Finance and Stock Titan news items, the company is advancing a pipeline that includes ACR-7280, an oral CDK11 inhibitor targeting an IND filing in the first half of 2027, and ACR-2316, a WEE1/PKMYT1 inhibitor with early Phase 1/2 results.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Acrivon Therapeutics Inc. (ACRV) reported $235.5M in annual revenue (up from $249.8M in FY2024, -5.7% YoY) and -$77.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($187.9M revenue, -$60.4M net income) through FY2025, ACRV scaled operating cash flow to -$63.7M and free cash flow to -$65.3M, backed by $129.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 4/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $1.27 – $3.56 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should watch for clinical readouts and regulatory milestones in the biotech sector generally, but no specific second-order linkages are established in the data.

Key Question #1: Can ACRV sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $235.5M and free cash flow of -$65.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is ACRV's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ACRV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Acrivon Therapeutics Inc. (ACRV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ACRV Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Acrivon Therapeutics, Inc. (ACRV) Seasonal returns chart

Yahoo Finance UK report covering Acrivon Therapeutics Inc. (ACRV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An automatic tax-withholding sale covers 513 shares of Acrivon Therapeutics (ACRV).

Stock Titan report covering Acrivon Therapeutics Inc. (ACRV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 2d ago

Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

Yahoo Finance report covering Acrivon Therapeutics Inc. (ACRV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 2d ago

Acrivon Therapeutics (ACRV) Grinds Higher: Micro-Cap Biotech Ticks Up 1.08% to $1.88 - IV Percentile

https://www.siam.in/ report covering Acrivon Therapeutics Inc. (ACRV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 2d ago

A drug candidate from Acrivon produced complete tumor regression in mouse leukemia models.

Stock Titan report covering Acrivon Therapeutics Inc. (ACRV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 2d ago

Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium

Yahoo Finance report covering Acrivon Therapeutics Inc. (ACRV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 2d ago

Vistagen Therapeutics, Inc. (VTGN) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Acrivon Therapeutics Inc. (ACRV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance UK • 2d ago

Gain Therapeutics, Inc. (GANX) Seasonal returns chart

Yahoo Finance UK report covering Acrivon Therapeutics Inc. (ACRV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ACRV Bull vs. Bear Conversation Board — What's Your Call at $1.61?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACRV 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $2.07 (+24.7%)

📌 Pinned Debate

Early clinical data for ACR-2316 is slated for a late-breaking oral plenary, offering a potential pipeline catalyst against a $75.4M ma

Don't sleep on ACRV's setup in Health Care. Early clinical data for ACR-2316 is slated for a late-breaking oral plenary, offering a potential pipeline catalyst against a $75.4M market cap.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (33/100) backs up the fundamental quality.

ArenaChamp_24 🐂 BULL

@DeepValue_CFA Agree on the RQD 33/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.66 and keeping dry powder in case we test $1.54.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $1.38 (-16.9%)

Spot @ $1.66

With ROIC at -35%, FCF of -$65.3M in FY 2025 against $41.5M cash, and a Piotroski F-Score of 3/9, the balance sheet shows limited runwa

I respect the product at Acrivon Therapeutics Inc., but the stock at $1.66 is a different story. With ROIC at -35%, FCF of -$65.3M in FY 2025 against $41.5M cash, and a Piotroski F-Score of 3/9, the balance sheet shows limited runway.. FCF yield is 0.0% and RQD sits at 33/100 (E) — why pay up here when you can wait for next quarter's numbers?